![](https://www.diabetesnews.com/wp-content/uploads/2014/04/insulin_0-150x150.jpg)
Cleveland-based Thermalin said today that JDRF will provide it with up to $1 million for specific milestones related to identifying a clinical candidate insulin analog with a shorter tail of action.
Read more
Cleveland-based Thermalin said today that JDRF will provide it with up to $1 million for specific milestones related to identifying a clinical candidate insulin analog with a shorter tail of action.
Read more